Studies on Activities and Chemical Characterization of Medicinal Plants in Search for New Antimalarials: A Ten Year Review on Ethnopharmacology

Isabela P. Ceravolo¹, Anna C. Aguiar², Joseph O. Adebayo³ and Antoniana U. Krettli¹*

¹Instituto René Rachou, Fundação Oswaldo Cruz (Fiocruz), Belo Horizonte, Brazil, ²Departamento de Biociência, Universidade Federal de São Paulo, Santos, Brazil, ³Department of Biochemistry, University of Ilorin, Ilorin, Nigeria

Malaria is an endemic disease that affected 229 million people and caused 409 thousand deaths, in 2019. Disease control is based on early diagnosis and specific treatment with antimalarial drugs since no effective vaccines are commercially available to prevent the disease. Drug chemotherapy has a strong historical link to the use of traditional plant infusions and other natural products in various cultures. The research based on such knowledge has yielded two drugs in medicine: the alkaloid quinine from Cinchona species, native in the Amazon highland rain forest in South America, and artemisinin from Artemisia annua, a species from the millenary Chinese medicine. The artemisinin-based combination therapies (ACTs), proven to be highly effective against malaria parasites, and considered as “the last bullet to fight drug-resistant malaria parasites,” have limited use now due to the emergence of multidrug resistance. In addition, the limited number of therapeutic options makes urgent the development of new antimalarial drugs. This review focuses on the antimalarial activities of 90 plant species obtained from a search using Pubmed database with keywords “antimalarials,” “plants” and “natural products.” We selected only papers published in the last 10 years (2011–2020), with a further analysis of those which were tested experimentally in malaria infected mice. Most plant species studied were from the African continent, followed by Asia and South America; their antimalarial activities were evaluated against asexual blood parasites, and only one species was evaluated for transmission blocking activity. Only a few compounds isolated from these plants were active and had their mechanisms of action delineated, thereby limiting the contribution of these medicinal plants as sources of novel antimalarial pharmacophores, which are highly necessary for the development of effective drugs. Nevertheless, the search for bioactive compounds remains as a promising strategy for the development of new antimalarials and the validation of traditional treatments against malaria. One species native in South America, Ampelozyzyphus amazonicus, and is largely used against human malaria in Brazil has a prophylactic effect, interfering with the viability of sporozoites in in vitro and in vivo experiments.

Keywords: malaria, antimalarials, medicinal plants, natural products, in vivo tests, ethnopharmacology
INTRODUCTION

Human malaria is an infectious disease caused by single-cell protozoan parasites of the *Plasmodium* genus, namely: *P. falciparum*, *P. vivax*, *P. ovale*, *P. malariae*, and *P. knowlesi*, and is transmitted through the bite of female *Anopheles* mosquitoes (Crompton et al., 2014; Singh et al., 2021); of these, *P. falciparum* is the most virulent and prevalent globally. Symptoms can range from a mild to severe disease which can cause important physical disabilities and death, with an enormous health burden, especially among the most vulnerable and poor populations. While *P. falciparum* is responsible for most deaths, *P. vivax* is the most widespread of all of the Plasmodium species, can cause severe, even fatal infections and results in significant global morbidity and mortality (Menkin-Smith and Winders, 2020). Recent studies have reported the virulence of *P. vivax* (Lampah et al., 2011; Tanwar et al., 2011); although, the proportion of cases due to *P. vivax* reduced from about 7% of the global malaria cases in 2000 to 3% in 2019 (WHO, 2020a).

Malaria is an endemic disease in the tropical and subtropical regions of the world. An estimated 229 million new cases and 409,000 deaths were recorded in 2019 (WHO, 2020a). About 94% of the global malaria cases and 95% of the deaths were recorded in the African region in 2019 (Figure 1), with children under the age of 5 years and pregnant women being the most susceptible groups (WHO, 2020a). Nigeria was responsible for 27% of the malaria cases and 23% of deaths globally in 2019 (WHO, 2020a); this high prevalence illustrated in Figure 2 (WHO, 2018a). This is because Nigeria is the most populous nation in Africa, with *P. falciparum* being the main cause of malaria (Adebayo and Krettli, 2011; WHO, 2020a). Actually, *P. falciparum* is the most predominant species in every country in sub-Saharan Africa; the countries with the highest number of malaria cases in West, East, Central and Southern Africa are shown in Table 1. In some countries in Africa, a hundred percent of the population is at risk of the disease (both low and high), such as Nigeria, Mozambique,
Democratic republic of Congo etc. (WHO, 2020a; Table 1). However, the numbers of reported cases in such countries are low compared to the expected numbers because of lack of access to diagnosis/health facilities or presumptuous treatment (Table 1). Ethiopia has been reported to have the highest number of P. vivax infections in Africa (WHO, 2020a). The higher prevalence of the disease based on the reported cases in the other regions of Africa compared to Southern Africa (Table 1) is an indication of favorable environmental conditions such as higher temperature and rainfall in such regions (Greenwood et al., 2008).

Drug chemotherapy has a strong historical link to the use of traditional plant infusions in various cultures. Research based on such knowledge has yielded the two most important drugs critical to malaria: the alkaloid quinine present in Cinchona species of highland rain forests in South America and artemisinin from Artemisia annua, first registered in the millenary Chinese medicine.

Artemisinin-based combination therapies (ACTs) are the most recommended treatments for uncomplicated P. falciparum malaria, while artesunate is considered the most effective antimalarial drug for severe cases (Roussel et al., 2017), with several biochemical processes reported as targets in the parasites (Wicht et al., 2020). Despite the safety and efficacies proven for the use of these antimalarial drugs, the emergence of multidrug resistance has unfortunately limited their effects and challenged the field (Nieves et al., 2016). The resistance to ACTs is already spreading from Southeast Asia as reported in 2008 (Noedl et al., 2008), giving rise to a danger alert to other high-poverty regions in the world. The unidentified artemisinin resistance phenotype is associated with mutation of a kelch domain protein gene (k13), postulated to be involved in the parasite protein trafficking organelles during the intraerythrocytic cycle (Ariey et al., 2014). This mutation has recently been reported in East Africa (Uwimana et al., 2020; Asua et al., 2021), Papua New Guinea (Miotto et al., 2020), and French Guiana (Mathieu et al., 2020); yet, there is limited evidence of delayed parasite clearance after ACT treatment in these regions (Yeka et al., 2016).

The treatment failure associated with ACTs in Africa has been linked to resistance of parasite to the partner drugs and not to artemisinin resistance (Slater et al., 2016). However, Ala675Val mutation in the kelch 13 propeller gene was seen in 5% of isolates in Northern Uganda and this mutation has been known to cause delayed parasite clearance in Southeast Asia (Asua et al., 2019). In the African continent, four countries have identified mutations associated with therapeutic failure of artemisinin derivatives. However, Pfk13 mutations (M476I, P553L, R561H, P574L, P650L, and L580F),
treatments in the absence of antimalarial drugs (Willcox, 2011).

Due to the resistance and the high cost of the potent ACTs, the poor populations of the African continent rely heavily on herbal remedies based on historical and cultural beliefs (Adebayo and Krettli, 2011). In addition, the limited number of therapeutic options makes the development of new antimalarial drugs urgent. The search for bioactive compounds from plants remains a promising strategy for the development of new antimalarial candidates as well as the validation of traditional treatments. In such context, the aim of this study was to review the literature for activities and safety of antimalarial plants in vivo and their isolated active principles studied during the last 10 years.

**History of Natural Products and Their Applications in the Treatment of Human Malaria**

The history of medicine dates back to the existence of human civilization. Most new drugs have been generated from natural products (secondary metabolites) and from compounds derived from natural products (Patwardhan et al., 2004; Lahlou, 2007). Natural products from plants, animals, and minerals, have been the basis of treatment of human diseases (Lahlou, 2007); nevertheless, plants used in traditional medicine may hold the key of many potent antimalarial drugs (Rasanoaivo et al., 2004).

Studies of plants used in traditional medicine for the treatment of malaria in various cultures have yielded important findings that are crucial to modern medicine. Two of the most effective drugs for malaria originated from traditional medicine: quinine from bark of Peruvian *Cinchona* tree, and artemisinin from the Chinese antipyretic *Artemisia annua* (Rasanoaivo et al., 2004).

Currently, standardized antimalarial phytomedicines are officially commercialized in various malaria endemic countries over the world, namely China, Ghana, India, Mali, and Burkina Faso (Abay et al., 2015), supporting their use as complementary tools to the conventional antimalarial interventions or as alternative treatments in the absence of antimalarial drugs (Willcox, 2011). Examples of herbal therapies are represented by Qing hao (*Artemisia annua*, Democratic Republic of Congo trials), Totaquina (*Cinchona* spp., Multicounty trials) and Phyto-laria (*Cryptolepis sanguinolenta*, Ghana trial) (Willcox, 2011). Medicinal plants are also used to treat malaria in several African countries (Soh and Benoit-Vical, 2007; Pillay et al., 2008; Adebayo and Krettli, 2011; Maranz, 2012; Chinsembu, 2015; Memvanga et al., 2015; Omara et al., 2020). In Ethiopia, 80% of the rural populations rely on medicinal plants to treat diseases due to the high cost of drugs, low access to health services, among other factors. As a result, many species of medicinal plants are used against malaria there, such as *Artemisia annua*, *Ajuga remota*, *Azadirachta indica*, *Argemone mexicana*, *Vernonia amygdalina*, *Asparagus africanus*, *Uvaria leptocladoan*, and *Gossypium* spp (Alebie et al., 2017).

**Quinine**

Historical records show that in 1638, the countess of Chinchón, wife of the Spanish viceroy in Peru, suffered a severe fever, which was later known as malaria. When ingesting a portion made by the Indians called “quina-quina” the fever subsided, and the continuity of treatment left her cured (Willcox et al., 2004; Ruiz-Irastorza and Khamashta, 2008; de Oliveira and Szczerskowski, 2009). There is also a reference that the use of *Cinchona* species in medical practice came to Belgium in 1643, when a public health official in Ghent recommended a powder for the treatment of tertian fevers (Jarcho and Torti, 1993). However, the first indisputable reference is the Schedula Romana, a hand bill issued by the Pharmacy of the Collegio Romano in 1649 and again in 1651, containing precise instructions on its dosage and administration (Jaramillo-Arango, 1949).

Before 1820, the bark of a tree native to South America named *Cinchona*, was dried, ground to a fine powder, and mixed into a liquid (commonly wine) before being used (Achan et al., 2011). The Jesuit priests of the Spanish mission took the tree bark to Europe to sell its powder as medicine against intermittent fevers. Later on, two French chemists, Pelletier and Caventou (1820), isolated the active principle by precipitation and crystallization and discovered that the base febrifuge compounds were the alkaloids named cinchonine and quinine. From it, the alkaloids quinine and cinchonidine were also described (Willcox et al., 2004; Kaufman and Ruveda, 2005). The four alkaloids from *Cinchona* bark were all effective against malaria, but quinidine and quinine possessed equal febrifugal activity, while cinchonidine was slightly less efficacious. An additional 25 alkaloids related to quinine had been isolated by 1884 and six more were isolated between 1884 and 1941 (Turner and Woodward, 1998). By the turn of the 18th and 19th centuries, *Cinchona* bark and quinine became widely accepted and used instead of the powdered bark as the reference treatment for intermittent fevers throughout the world (Gachelin et al., 2017).

During the second World War, there was an interruption in the supply of *Cinchona* bark, which contained a high amount of quinine, from the Java island where the seeds were largely

![FIGURE 3 | Chemical structure of quinine. Source: https://commons.wikimedia.org/wiki/File:Quinine_structure.svg.](https://commons.wikimedia.org/wiki/File:Quinine_structure.svg)
Quinine is still used as monotherapy to treat malaria today in most countries of Africa and in some Central American, Caribbean, Eastern Mediterranean, South-East Asian and Western Pacific countries (WHO, 2019). In several settings, the use of quinine for uncomplicated malaria cases has reduced due to toxicity, poor compliance, and the implementation of newer and better tolerated therapies. However, from frequent stock-outs of the recommended ACT and the increasing resistance to chloroquine and antifolates, quinine use in recent times has increased (Wasunna et al., 2008; UMSP, 2010).

The 2015 World Health Organization (WHO) guidelines recommend a combination of quinine and clindamycin, or only quinine to treat pregnant women with uncomplicated *P. falciparum* and who have chloroquine-resistant *P. vivax* malaria during the first trimester. For the treatment of severe malaria of adults and children, it is essential that full doses of effective parenteral (or rectal) antimalarial treatment be given promptly in the initial treatment (WHO, 2015). The *Cinchona* alkaloids quinine and quinidine are the second choice, after artemisinin derivatives. When a complete oral treatment of severe malaria is not possible, but injections are available, the intramuscular quinine could be used if artemesunate or artemether is not available (WHO, 2015).

**Artarminisin**

Qinghao (“blue-green herb”) is the Chinese name for a relatively common herbal plant otherwise known as *Artemisia annua* or sweet wormwood (Maude et al., 2010). *Artemisia annua* is native to Asia (China, Japan, Korea, Vietnam, Myanmar, Northern India, Southern Siberia and throughout eastern Europe) (WHO, 1998), but it also grows in other countries such as Congo, India, Brazil, Australia, Argentina, Bulgaria, France, Hungary, Italy, Spain, and the USA (Willcox et al., 2003; Zhou et al., 2014). There is an integral interaction between plants, the environment and the production of secondary metabolites, which can directly interfere with their quantities and qualities (Kutchan, 2001). The artemisinin content is affected by several factors, such as geographic conditions, harvest time, temperature and fertilizer application; harvesting the plant at the right time is extremely important to ensure the optimal artemisinin content in *A. annua*. Thus, for the cultivation of this medicinal plant, it is important to...
plan the crop establishment for the beginning of the rainy season, and the soil needs to be plowed to a fine slope and consolidated by rolling when appropriate, because the sowing depth is also critical for *A. annua* (Jelodar et al., 2014). This means that not all *A. annua* plants have high concentrations of antimalarial compounds.

The *A. annua* has been used as a remedy by Chinese herbalists for the crafting of aromatic wreaths, as a source of essential oils used in flavoring vermouth, and for more than 2,000 years in Chinese traditional medicine, as a treatment for fever and hemorrhoids (Van Agtmael et al., 1999; Klayman, 1985). *Artemisia annua* is also used as a source of artemisinin (Zhou et al., 2014), a potent antimalarial drug discovered by the Chinese scientists led by Youyou Tu, that was awarded the 2011 Lasker Prize and the Nobel Prize in Physiology or Medicine in 2015 (Youyou, 2015). The project leading to the discovery of artemisinin was initiated in response to a request from North Vietnamese leaders who were suffering heavy losses of soldiers due to malaria during the Vietnam War (Cui and Su, 2009). The drug is present in the leaves and flowers of the plant accounting for approximately 0.01–0.8% of dry weight (Van Agtmael et al., 1999). Chemically, artemisinin is a sesquiterpene trioxane lactone containing a peroxide bridge (Figure 4), which is essential for its activity (China Cooperative Research Group, 1982).

The earliest known record of *A. annua* was in the book 52 Prescriptions, discovered in the Mawangdui tomb of the Han Dynasty in 168 BC, where it was first described for the treatment of hemorrhoids (Qinghaosu Antimalarial Coordinating Research Group, 1979; Klayman, 1985). Around 340 AD, in Hong Ge’s Handbook of Prescriptions for Emergency Treatment, a cold extraction method of qinghao was described for the treatment of intermittent fevers (Klayman, 1985). Qinghao has also been mentioned in several later standard Chinese Materia Medica texts as treatment for fever (Qinghaosu Antimalarial Coordinating Research Group, 1979; Hien and White, 1993); it has also been used for haemorrhoids, lice, wounds, boils, sores, and convulsions (Hsu, 2006).

The active ingredient of qinghao, artemisinin, was isolated from the plant *A. annua* in 1972 by a group of Chinese scientists (Hien and White, 1993). In 1975, its unique chemical structure was elucidated, as a sesquiterpene lactone bearing a peroxoy group, which is believed to be responsible for the antimalarial activity of *A. annua* (Willcox et al., 2003), and is quite different from those of all known antimalarial drugs (Liu et al., 1979), then the name qinghaosu ("active principle of qinghao") was changed to artemisinin (Klayman, 1985). Its structure was determined by X-ray analysis in 1979 (Balint, 2001; Krishna et al., 2008). Further studies led to the development of more stable derivatives, such as dihydroartemisinin, artemether, artemotil (arteether) and artesunate (Ansari et al., 2013).

Artemisinin and its derivatives produce rapid parasite clearance, killing young circulating parasites more than the other forms of the parasite, before they are sequestered in the deep microvasculature (Dondorp and Von Seidlein, 2017). This phenomenon is important in the pathogenesis of malaria because mature parasites are able to adhere to endothelial cells, blood cells and platelets, which prevent their circulation in the bloodstream and they will therefore be able to escape clearance by the spleen (Buffet et al., 2011). This is clinically relevant, particularly in the cases of cerebral and severe malaria (Hsu, 2006). These drugs interact with heme to produce carbon-centered free radicals that alkylate protein and damage the microganelles and membranes of the parasites (Meshnick, 1998), significantly faster than any other antimalarial does (Willcox et al., 2003; Siram et al., 2004). Unlike the quinine-related drugs and antifolate drugs, artemisinin and its derivatives are also gametocytocidal and reduce the transmission of malaria by *P. falciparum* (Price et al., 1996).

Since 1994, artemisinins have been used in artemisinin-based combination therapies (ACTs) to treat uncomplicated malaria (Ouji et al., 2018), and by 2006, ACTs had become the recommended treatments for falciparum malaria worldwide (WHO, 2015). The artemisinin derivatives are usually combined with a more slowly eliminated drug in ACTs (Ansari et al., 2013). In this case, the role of the artemisinin compound is to reduce the number of parasites during the first 3 days of treatment (reduction of parasite biomass), while the role of the partner drug is to eliminate the remaining parasites leading to a malaria cure. ACTs are also recommended by WHO for chloroquine-resistant *P. vivax* malaria, and the injectable artesunate and artemether, are recommended for the treatment of severe malaria (WHO, 2018b).

ACTs are the most effective antimalarial medicines available today, but there are already cases of resistance to artemisinin and its derivatives. Artemisinin resistance in Cambodia was first identified in clinical studies in 2006, and few years later in Myanmar, Thailand, Viet Nam, and Lao. However, retrospective analysis of molecular markers indicated that artemisinin resistance probably emerged in 2001, before the widespread deployment of ACTs in Cambodia (Noedl et al., 2008; Dondorp et al., 2009; WHO, 2017). In spite of the fact that WHO continues to monitor cases of resistance to artemisinin and its derivatives, new drugs must be discovered to overcome the problem of the development of resistance that can make its use unfeasible in the future.

**Current Malaria Treatment**

ACTs are recommended by WHO as the first-and second-line treatment for uncomplicated *P. falciparum* malaria, as well as for chloroquine-resistant *P. vivax* malaria. The role of the artemisinin compound is to reduce the number of parasites during the first 3 days of treatment (reduction of parasite biomass), while the role of the partner drug is to eliminate the remaining parasites, leading to cure (WHO, 2018b). It is recommended to use a 3-day treatment regimen with one of the five different ACTs, namely artetemether/lumefantrine, artesunate/amodiaquine, artesunate/mefloquine, dihydroartemisinin/piperaquine or artesunate/sulfadoxine-pyrimethamine. ACTs are not recommended in the first trimester of pregnancy for uncomplicated *P. falciparum* malaria; the World Health Organization guidelines (WHO, 2015) recommends a combination of quinine and clindamycin, or only quinine for uncomplicated malaria caused by *P. falciparum* and by chloroquine-resistant *P. vivax*. 


In areas with chloroquine-sensitive *P. vivax*, *P. ovale*, *P. malariae* or *P. knowlesi* infections, the adults and children are treated with ACTs or chloroquine. Primaquine can be administered to avoid relapses of vivax malaria in people with malaria treated with ACTs or chloroquine. Primaquine can be used in preference to quinine (WHO, 2015).

### METHODS

#### Study Selection and Analysis

The flowchart (Figure 5) demonstrates the strategy used for identification, and the criteria for inclusion and exclusion of the plants in the present review. A total of 321 articles were initially retrieved from the database PubMed in the last 10 years (2011-2020) using the keywords “antimalarials,” “plants” and “natural products.” Some additional references of other articles published before have been also included, although they were not found after using the keywords. In a further analysis, articles which focused on the plant species tested *in vivo* against malaria, using mice infected with *Plasmodium* species, were selected. This gave a total of 91 full articles, from which 19 articles were excluded because: 1) they were in other languages rather than English; 2) the reported chemosuppression was below 30%, which did not correspond to the criteria for antimalarial activity, as defined below; 3) the tests were with polyherbal extracts rather than with one species of plant; 4) the active plants were toxic; 5) the tests against early sporogonic stages were conducted *ex vivo*; or, 6) the studies were performed using plants associated or in combination with antimalarial drugs. After applying all these requirements, the total number of publications evaluated was 72, as shown in Table 2 and Figure 5.

In this review natural products mostly from medicinal plants were considered active when inhibition of parasite growth was equal to or above 30% (the lower limit for moderately active products); those below 30% were considered to be inactive (Carvalho et al., 1991; Andrade-Neto et al., 2003; Coutinho et al., 2013; Induli et al., 2013; Musila et al., 2013; Nguta and Mbaria, 2013; Bantie et al., 2014; Upadhyay et al., 2014; Aguiar et al., 2015; Rocha e Silva et al., 2015; Satish et al., 2017).

### RESULTS AND DISCUSSION

The scientific names of the plant species tested, their botanical families, parts of the plants fractionated, the ethnomedicinal uses and the countries where the studies were performed are shown in Table 2. Among the 72 articles, 54 of them evaluated the antimalarial activities of one plant species each while 18 of them evaluated two or three plant species each, giving rise to a total of 90 plant species, some of which were studied by more than one author. The three most studied families were Fabaceae, Apiaceae and Lamiaceae. The plant species evaluated for antimalarial activities corresponded to 44 botanical families; the parts of the plants tested were aerial parts, leaves, leaf latex, rhizomes, roots, root bark, stem bark, whole stem, branches, twigs, petiole, cortex, flower, fruits, fruit pulp, unripe fruits, and whole plant (Table 2).

A total of 60 of the 90 medicinal plant species (66.67%) tested in mice with rodent *Plasmodium* species were recommended for the treatment of malaria and/or malaria prevention, as well as for other ailments; six species (6.67%) were used against fever in general, which happens to be the main acute symptom of human malaria. A total of 15 species (16.67%) had an ethnopharmacological recommendation for other diseases and morbidities rather than malaria, while nine species (10%) did not have their ethnomedicinal uses mentioned (Figure 6A).

Further information about the plant species studied are depicted in Table 2. Most studies regarding the antimalarial activities of plant species using animal models, were performed presumably where the plant species occur and/or are native: 59 of the species were in the African continent (65.56%), 18 species were in Asia (20%) and 13 species were in South America (14.44%) (Figure 6B).

Regarding the countries where the studies were performed in mice infected with malaria parasites, an African country had the highest number, that is Ethiopia (Africa, n = 29), followed by Brazil (South America, n = 11), India (Asia, n = 10) and Nigeria (Africa, n = 10) (Figure 7).
| Family* | Plant species | Part(s) used | Ethnomedical use | Country | Reference |
|---------|---------------|-------------|------------------|---------|-----------|
| Anacardiaceae (2) | Anacardiaceae (2) | | | | |
| Polyalthia longifolia | Anacardiaceae (2) | Stem bark, leaves | Malaria and others | Ethiopia | Derebe and Wubetu (2019), Kifle and Athane (2020) |
| Adansonia digitata | Bombacaceae (1) | | | | |
| Polyalthia longifolia | Bombacaceae (1) | | | | |
| Xylopia amazonica | Bombacaceae (1) | | | | |
| Averrhoa bilimbi | Bombacaceae (1) | | | | |
| Bombax buonopozense | Bombacaceae (1) | | | | |
| Cordia africana | Bombacaceae (1) | | | | |
| Terminalia brownii | Bombacaceae (1) | | | | |
| Combretaceae (2) | Combretaceae (2) | | | | |
| Terminalia macropera | Combretaceae (2) | | | | |
| Cucurbitaceae (3) | Cucurbitaceae (3) | | | | |
| Citrullus colocynthis | Cucurbitaceae (3) | | | | |
| Cucumis metuliferus | Cucurbitaceae (3) | | | | |
| Gynostemma pentphyllum | Cucurbitaceae (3) | | | | |
| Euphorbiaceae (2) | Euphorbiaceae (2) | | | | |
| Croton macrostachyus | Euphorbiaceae (2) | | | | |
| Phyllanthus nicosus | Euphorbiaceae (2) | | | | |
| Fabaceae (11) | Fabaceae (11) | | | | |
| Acacia karroo | Fabaceae (11) | | | | |
| Acacia nilotica | Fabaceae (11) | | | | |
| Asclepias curassa | Fabaceae (11) | | | | |
| Cassia fistula | Fabaceae (11) | | | | |
| Commiphora africana | Fabaceae (11) | | | | |
| Copaifera reticulata | Fabaceae (11) | | | | |
| Dichrostachys cinerea | Fabaceae (11) | | | | |
| Glicyrrhiza glabra | Fabaceae (11) | | | | |
| Indigofera spicata | Fabaceae (11) | | | | |
| Pongamia pinnata | Fabaceae (11) | | | | |
| Tamarindus indica | Fabaceae (11) | | | | |
| Gentianaceae (1) | Gentianaceae (1) | | | | |
| Anthoceclusa elatum | Gentianaceae (1) | | | | |
| Iacina senegalensis | Gentianaceae (1) | | | | |
| Icacinaceae (1) | Icacinaceae (1) | | | | |
| Acanthus polystachyus | Icacinaceae (1) | | | | |
| Acanthus polystachyus | Icacinaceae (1) | | | | |
| Acanthus polystachyus | Icacinaceae (1) | | | | |

(Continued on following page)
TABLE 2 | (Continued) Botanical classification, ethnomedical uses of plants evaluated for antimalarial activity in mice infected with Plasmodium species, and countries of studies from 2011 to 2020.

| Family* | Plant species | Part(s) used | Ethnomedical use | Country | Reference |
|---------|---------------|--------------|------------------|---------|-----------|
| Lamiaceae (7) | Ajuga bracteosa | Leaves | Malaria and other effects | India | Chandel and Bagai (2011) |
| | Ajuga integrifolia | Aerial parts | Malaria | Ethiopia | Asnake et al. (2015) |
| | Leonotis ocymifolia | Leaves | Malaria, yellow fever and others | Ethiopia | Teklu et al. (2020) |
| | Ocimum sanctum | Leaves | To enhance immunity and other effects | India | Rajendran et al., 2014 |
| | Ocimum suave | Leaves | Malaria | Kenya | Kraithe et al. (2016) |
| | Plecitranthus barbatus | Root bark | Malaria | Kenya | Kraithe et al. (2016) |
| Meliaceae (4) | Azadirachta indica | Leaves | Malaria, yellow fever and other effects | Ethiopia | Mesfin et al. (2012) |
| | Entandrophragma cylindricum | Stem bark | Malaria | Cameroon | Nadia et al. (2020) |
| | Melia azedarach | Twigs | Malaria | Ethiopia | Asnake et al. (2015) |
| | Trichila heudelotii | Stem bark | Malaria | Nigeria | Bankole et al. (2016) |
| Monocotae (1) | Ficus thonningii | Leaves | Several uses, non-antimalarial | Nigeria | Falade et al. (2014) |
| Moringaceae (1) | Moringa oleifera | Leaves | Antioxidant and other effects | Thailand | Somsaik et al. (2016) |
| Myricaceae (1) | Myrica salicifolia | Roots | Malaria | Ethiopia | Kifle et al. (2020) |
| Myrtaceae (2) | Psidium guajava | Leaves, unripe fruits | Broad spectrum of activities | India | Rajendran et al. (2014) |
| | Syzygium cumini | Leaves | Pyretic diseases | India | Sachdeva et al. (2020) |
| Ochnaceae (1) | Lophira alata | Leaves | Anti-fever and other uses | Nigeria | Falade et al. (2014) |
| Oleaceae (1) | Olea europaea | Stem bark, leaves | Malaria and other infections | Ethiopia | Misiganaw et al. (2019), Halesiase et al. (2020) |
| Picramniaceae (1) | Picramnia latifolia | Bark/petiole | Not found | Colombia | Berthi et al. (2018) |
| Piperaceae (1) | Piper petiolaris | Roots | Malaria | Brazil | Rocha e Silva et al. (2011) |
| Poisonos (1) | Andropogon leucostachyus | Aerial parts | Malaria | Brazil | Lima et al. (2015) |
| Ranunculaceae (1) | Coepis japonica | Rhizome | Inflammatory disease | Japan | Tekemichael et al. (2020) |
| Rheumaceae (1) | Ziziphus mauritiana | Leaves | Not found | Ivory Coast | Atteme et al. (2018) |
| Rosaceae (1) | Rubus ellipticus | Leaves | Pyretic diseases | India | Sachdeva et al. (2020) |
| Rubiaceae (3) | Canthium glauum | Roots | Malaria | Kenya | Musila et al. (2013) |
| | Gardenia ternifolia | Root bark | Malaria | Ethiopia | Nureye et al. (2018) |
| | Heinsia crinita | Leaves, fruits, stem bark | Malaria, fever and others | Congo | Tshisekedi et al. (2017) |
| Rutaceae (3) | Fagara zanthoxyloides | Leaves | Malaria | Nigeria | Enechi et al. (2019) |
| | Muraya koenigii | Leaves | Malaria and to decrease insulin level | India | Kamaraj et al. (2014), Rajendran et al. (2014) |
| | Zanthoxylum chalybeum | Root bark | Malaria | Kenya | Kraithe et al. (2016) |
| Sapindaceae (1) | Dodonaea angustifolia | Roots | Malaria | Ethiopia | Amelo et al. (2014) |
| Santalaceae (1) | Oryza quadrifolia | Roots | Malaria | Ethiopia | Girma et al. (2015) |
| Simaruvaceae (1) | Picrolemma huberi | Cortex | Not found | Colombia | Berthi et al. (2018) |
| Solanaceae (2) | Physalis alkekengi | Leaves and fruits | Anti-fever and other uses | Iran | Haddad et al. (2017) |
| | Solanum nigrum | Fruits | Not found | Iran | Haddad et al. (2017) |
| Stilbaceae (1) | Nuxia congesta | Leaves | Malaria | Ethiopia | Fenta and Kahale (2019) |
| | Strychnaceae (1) | Strychnos mitis | Leaves | Malaria | Ethiopia | Fenta et al. (2017) |
| | Tilaceae (1) | Grewia triochocarpa | Roots | Malaria | Kenya | Mwangi et al. (2015) |
| | Verbenaceae (1) | Lippia kitiensis | Leaves | Malaria | Tanzania | Misana et al. (2018) |
| | Zingiberaceae (1) | Zingiber officinalis | Roots | Malaria | Ethiopia | Bruksew et al. (2018) |
| | Zygophyllaceae (1) | Balanites rotundifolia | Leaves | Malaria | Ethiopia | Asrade et al. (2017) |

*Number of species studied by family in parentheses.

*Antimalarial activity evaluated against gametocytes.

Other details of the in vivo tests described in the original articles are summarized in Table 3. As expected, most medicinal plants exhibited antimalarial activities against Plasmodium species in mice experimentally infected (P. berghei or P. yoelli), though some active doses were too high. These doses are not feasible under clinical settings, making such extracts of no clinical relevance. The results validated the ethnobotanical uses of several plants in malaria endemic countries as they reduced parasitaemia and were well tolerated by the uninfected mice (Table 3). The active doses of the extracts from medicinal plants tested in mice infected with rodent malaria species ranged from 1 to 6,000 mg/kg, although there was no clear relationship between doses and percentage inhibition of parasite growth, in several cases. The mean survival time was assessed for 65 (72.2%) of the species evaluated; for 55 of them (84.6%), there was an increase in the survival time of the treated mice while for 10 plant species (15.4%) there was no change in the time of animal survival, as compared to the untreated malaria controls (Table 3). The acute toxicity was evaluated for 40 of the 90 plant species; the LD50 values for 37
species (41.1%) were 2,000 mg/kg body weight or above (Table 3), and six of the plant species had LD₉₀ values equal to or higher than 5,000 mg/kg body weight, suggesting that these plant extracts were not toxic (Lorke, 1983).

The most active species was *Heliantus annuus* (popularly known as sunflower) in tests using ethanolic extract of the leaves, which caused a high suppression of parasitemia (49, 76, and 82% using oral doses of 1, 10 and 100 mg/kg, respectively). Its mechanism of action was through the *in vitro* inhibition of heme polarization by the parasites in a dose dependent manner. Extracts of other parts of the plant species, including roots, stems and flowers (Table 3) were also highly active (Ekasari et al., 2019; Ekasari et al., 2020), but the toxicity of the extracts was not evaluated, perhaps because the sunflower oil from seeds is largely used all over the world in food preparation.

Medicinal plants are often used in health care delivery as complementary and/or alternative medicines against human malaria, specially in poorer areas of the African countries. Such use may be important, especially in conjunction with other health measures like mosquito bed-nets, repellents, and/or treatments with an antimalarial, including the inexpensive chloroquine pills, that costs about 10 US cents per course of treatment for an adult (Institute of Medicine, 2004).

The usefulness of traditional medicinal plants as antimalarials, as judged from the work herein analysed, is relevant, though some of the experimental work have not confirmed a dose response activity in the rodent malaria model, suggesting that they lack relevant activity. In addition and also importantly, in most studies organic solvents were used for the extraction of the plant materials tested, despite the fact that it has been recommended that only water and ethanol should be used in traditional preparations (Willcox et al., 2011). Therefore,
| Plant species       | Parasitemia Inhibition with each extract and dose used for the treatment of the malaria infected mice (dose in mg/kg body weight) | Increased survival of the malaria infected mice | Safe dose to non-infected mice (mg/kg body weight) |
|---------------------|-----------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Acacia karroo      | Methanolic leaf extract 57% (500)                                                                                  | NE                                              | NE                                              |
| Acacia nilotica    | Aqueous root fraction F-1 77% (100)                                                                               | Yes                                             | NE                                              |
| Acacia nilotica    | Methanolic leaves extract 34% (200), 49% (400) [Kiffe and Atnafie, 2020]                                         | Yes                                             | NE                                              |
| Acokanthera schimperi | Methanolic leaf extract 37% (600)                                                                                 | Not improved                                    | 2,000                                           |
| Adansonia digitata | Aqueous stem bark extract 60% (100), organic stem bark extract 33% (100)                                          | NE                                              | LD$_{50}$ >1,000 µg/ml                          |
| Aloe sp            | Ethanolic leaf extract 74% (650), aqueous leaf extract 58% (650)                                                  | Not improved                                    | 3,000                                           |
| Aloe pinnatae      | Ethanolic latex extract 39% (400), 47% (600)                                                                       | Yes                                             | NE                                              |
| Aloe weberiella    | Aqueous leaf latex extract 42% (200), 67% (400)                                                                    | Yes                                             | 2,000                                           |
| Ajuga bracteosa    | Ethanolic leaf extract 67% (250), 80% (500), 85% (750)                                                            | Yes                                             | NE                                              |
| Ajuga integrioloxa | Methanolic aerial part extract 36% (800)                                                                         | Yes                                             | 2,000                                           |
| Andropogon leucoastachyus | Hydroethanolic stem bark extract 36% (200), 48% (400), 71% (600)                                                  | Yes                                             | NE                                              |
| Anthocleista djalonensis | Ethanolic wood bark fraction 79% (100), 58% (200)                                                                     | Not improved                                    | NE                                              |
| Aspidosperma nitidum | Ethanolic wood extract 48% (250); chloroform fraction 43% (250); methanolic extract >67% (100); fraction from methanolic extract >48% (100); FO IV 65% (50); precipitate fraction 57% (50) | Yes                                             | NE                                              |
| Aspidosperma olivaceum | Acetic stem bark fraction 79% (100); 58% (200)                                                                         | Not improved                                    | NE                                              |
| Aspidosperma pyrifolium | Root bark extract 79% (100), root extract 75% (100); aqueous stem bark fraction 93% (100); alkaloid-rich stem fraction 79% (100) | Yes                                             | NE                                              |
| Aspidosperma ramiflorum | Methanolic stem bark neutral precipitate extract 66% (250) and 53% (500)                                             | Yes                                             | NE                                              |
| Azadirachta indica | Ethanolic leaf extract 55% (650)                                                                                  | Not improved                                    | 3,000                                           |
| Balanites rotundifolia | Methanolic leaf extract 37% (100), 42% (200), 67% (400)                                                            | Yes                                             | 2,000                                           |
| Bombax buonopozense | Aqueous root bark extract 81% (50), 86% (100), 93% (200)                                                             | Yes                                             | 5,000                                           |
| Caesalpinia bonducvela | Dichloromethane root extract 38% (400)                                                                            | Yes                                             | NE                                              |
| Caesalpinia pluviosa | Ethanolic stem bark Fraction F4 79% (50)                                                                         | NE                                              | NE                                              |
| Calotropis gigantea | Methanolic leaf extract 41% (100); 52% (200); 65% (400); 72% (800); 74% (1,000)                                   | Yes                                             | NE                                              |
| Canthium glaucum   | Aqueous root extract 32% (100), organic extract 44% (100)                                                          | Yes                                             | LD$_{50}$ >1,000 µg/ml                          |
| Chenopodium ambrosioides | Hydroalcoholic leaf extract 63% (5)                                                                                | Yes                                             | NE                                              |
| Citrullus colocynthis | Methanolic fruit extract 65% (50)                                                                                  | Yes                                             | NE                                              |
| Commiphora africana | Dichloromethane bark extract 64% (400)                                                                            | Yes                                             | NE                                              |
| Copallina relictula | Oleoresin 96% (100), 93% (200)                                                                                    | Yes                                             | 2,000                                           |
| Coptis japonica    | Aqueous rhizome extract 50% (122); coptisine chloride 89% (365)                                                   | NE                                              | NE                                              |
| Cordia africana    | Methanol leaf extract 51% (600), butanol fraction 56% (400), chloroform fraction 45% (400)                       | Yes                                             | 2,000                                           |
| Croton macrostachyus | Methanol leaf extract 44% (200), 78% (400), 91% (600); chloroform fraction 49% (200), 66% (400), 76% (600); methanol fraction 37% (200), 53% (400), 64% (600); aqueous fraction 39% (600) (Bantie et al., 2014); methanolic leaf extract 34% (600), aqueous leaves extract 31% (400), 51% (600) (Mohammed et al., 2014) | Yes                                             | 5,000 or 2,000 |
| Cucumis meloferus  | Chloroform extract 46% (300), 80% (600), 99% (1,500), methanolic extract 37% (300), 59% (600), 89% (1,500), ethyl acetate extract 31% (300), 64% (600), 84% (1,500) | Yes                                             | NE                                              |
| Dichrostachys cinerea | Dichloromethane bark extract 53% (400)                                                                            | Yes                                             | NE                                              |
| Dicoma tomentosa    | Ethanolic 50% whole plant extract 90% (300); aqueous whole plant extract ~80% (300); methanol whole plant extract ~40% (100); methanolic + ethanolic 50% extract ~40% (100) | Yes                                             | NE                                              |
| Dodonaea angustifolia | n-butanol root fraction 38% (200), 56% (400), 68% (600); chloroform root fraction 37% (400), 42% (600)                | Yes                                             | 2,000                                           |
| Dausus virgatus*    | Methanolic aerial part Dauusovgolde G 92% (50 µg/ml)                                                               | NE                                              | NE                                              |
| Echinops hoehnelii | Methanolic root extract 69% (200), 79% (400); dichloromethane fraction 34% (200), 43% (400); fractions from 5-penta-1, 3-diylnyl-2-(3,4-dihydroxybut-1-ynyl)-thiophene 43.2% (50) and 50% (100); 5-penta-1,3-diylnyl-2-(3-chloro-4-aceoxy-but-1-y1)-thiophene 33% (100) | Yes                                             | NE                                              |
| Echinops kebericho | Ethanolic rhizome extract 58% (500) (Toma et al., 2013); methanolic root extract 35% (500), 50% (1,000) (Biruksew et al., 2018) | Yes                                             | 5,000                                           |
| Entandrophragma cyrdiculum | Ethyl acetate stem bark extract 99% (250), 100% (500)                                                              | Yes                                             | NE                                              |
| Euterpe oleracea    | Aqueous fruit pulp fraction 1 (total phenolics) 89% (20)                                                           | Yes                                             | 5,000 or 2,000 |
| Fagara zanthoxyloides | Methanolic leaf extract 82% (200), 91% (400), 96% (600)                                                            | Yes                                             | NE                                              |

(Continued on following page)
TABLE 3 | (Continued) Antimalarial activities and toxicities of medicinal plants evaluated in animal models from 2011 to 2020.

| Plant species | Parasitemia Inhibition with each extract and dose used for the treatment of the malaria infected mice (dose in mg/kg body weight) | Increased survival of the malaria infected mice | Safe dose to non-infected mice (mg/kg body weight) |
|---------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------|-----------------------------------------------|
| *Ferulago angustata* | Ethanolic aerial part extract 30% (100), 40% (300), 50% (600); superosin peroxidase 40% (10), 50% (30), 50% (75), 75% (100) | Yes | NE |
| *Ficus thonningii* | Hexane leaf extracts 65% (100), 71% (200), 76% (300), 83% (400), 85% (500) | Yes | NE |
| *Gardenia ternifolia* | Methanolic root bark extract 33% (200), 47% (400), 59% (600); butanol fraction 31% (200), 42% (400), 51% (600); chloroform fraction 31% (400), 41% (600) | Yes | 2,000 |
| *Glycyrriza glabra* | Butanolic root extract, 18β-glycyrrhetinic acid 68–100% (62.5–250) | NE | NE |
| *Grewia trichocarpa* | Aqueous root extract 36% (100) | Not improved | LC50 of 545.8 µg/ml |
| *Gynostemma pentaphyllum* | Aqueous leaf extract 45% (500), 50% (1,000), 55% (2,000) | Yes | NE |
| *Heinsea crinita* | Ethanolic extract: root 36% (1), 48% (10), 64% (100), 72% (250), 79% (400), 63% (600); stems 40% (100); seeds 42% (100); flowers 36% (100) (Ekasari et al., 2019); leaf 49% (1), 76% (10), 82% (100) (Ekasari et al., 2020) | Yes | NE |
| *Holarrhena pubescens* | Methanolic root extract 32% (400), 43% (800) | Not improved | NE |
| *Hypoestes forskalei* | Methanolic leaf extract 47% (200), 51% (400), 56% (600) | Yes | NE |
| *Iccinia senegalensis* | Ethanolic root extract 81% (50), 86% (100), 92% (200) | Yes | NE |
| *Indigofera spicata* | Methanolic root extract 17% (200), 35% (400), 53% (600) | Yes | NE |
| *Kniphofia foliosa* | Ethanolic leaf extract 17% (100), 19% (200), 23% (400) | No | NE |
| *Leonotis ocymifolia* | Ethanolic leaf extracts 65% (100), 71% (200), 76% (300), 83% (400), 85% (500) | Yes | 2,000 |
| *Lippia kituiensis* | Ethanolic leaf extract 36% (300), 69% (600), 75% (1,500); Chloroform leaf extract 64% (300), 70% (600), 94% (1,500); Ethyl acetate leaf extract 42% (300), 70% (600), 95% (1,500) | Yes | NE |
| *Lophira alata* | Hexane leaf extract 37% (200), 60% (300), 69% (400), 74% (500) | Yes | NE |
| *Markhania tormentosa* | Aqueous leaf extract 46% (250), 43% (500), 73% (800) | Yes | NE |
| *Melia azedarach* | Ethanolic aerial part extract 32% (800) | Yes | NE |
| *Moringa oleifera* | Aqueous leaf extract 35% (50), 40% (100), 50% (200) | Yes | NE |
| *Murraya koenigii* | Aqueous leaf extract 62% (350), 72% (750), 77% (1,000); ethyl acetate leaf extract 87% (600); myristic acid 83% (100); β-caryophyllene 88% (100) | Yes | NE |
| *Myrcia salicifolia* | Methanolic root extract 38% (100), 51% (200), 59% (400) | Yes | 2,000 |
| *Nuxia congesta* | Aqueous fruits extract 81% (650) | Yes | NE |
| *Ocimum lamifolium* | Ethanolic leaf extract 36% (600) | Yes | NE |
| *Ocimum sanctum* | Aqueous leaf extract 44% (750), 36% (1,000) | Yes | NE |
| *Ocimum suave* | Chloroform-methanolic leaf extract 55% (100) | Yes | NE |
| *Olea europaea* | Methanolic stem bark extract 30% (200), 43% (400), 52% (600); butanol fraction 35% (200), 45% (400), compound C 81% (100), 81% (200), 83% (500), 86% (600); fractions: chloroform 32% (200), 36% (400), 38% (600); butanol fraction 41% (200), 46% (400), 51% (600) | Yes | NE |
| *Oxys quadrifoliana* | Ethanolic leaf extract 41% (800) | Yes | NE |
| *Piper betel* | Chloroformic-ethanolic root extract, 4-Nerolidylcatechol 34% (400), 63% (600) | Yes | NE |
| *Plectranthus barbatus* | Chloroform-methanolic root bark extract 79% (100) | Yes | NE |
| *Polyalthia longifolia* | Aqueous leaf extract 53% (800) | Yes | NE |
| *Pongamia pinata* | Methanolic bark extract 84% (1,000) | Yes | NE |
| *Psidium guajava* | Aqueous extract: unripe fruits 30% (350), 65% (750), 62% (1,000); leaves 74% (350), 80% (750), 86% (1,000) | Yes | NE |
| *Rubus ellipticus* | Methanolic seed extract 64% (500) | Yes | NE |
| *Solanum nigrum* | Methanolic fruit extract 61% (100) | Yes | NE |
| *Sophora juponifolia* | Ethanolic fruit extract, compound 1 - 2,3,6-trihydroxy benzoic acid (1) 54% (50), 70% (100) | Yes | NE |
| *Strachys mithi* | Aqueous leaf extract 75% (400), 96% (600); hydro-methanolic leaf extract 36% (200), 81% (400), 94% (600) | Yes | NE |
| *Syzygium cumini* | Ethanolic leaf extract 52% (500) | Yes | NE |
| *Tamarindus indica* | Aqueous fruits extract 81% (600) | Not improved | 3,000 |
| *Terminalia brownii* | Methanolic bark extract 33% (100), 47% (200), 60% (400); aqueous bark extract 39% (200), 51% (400) | Yes | NE |

(Continued on following page)
with the present analysed data, it is difficult to evaluate the real pharmacological usefulness of medicinal plant extracted in organic solvents to serve as future bioproduct for the development of antimalarials.

**Tests of Medicinal Plants From Brazil Against Experimental Rodent Malaria**

In Brazil, plants and other natural products are rarely used to treat or prevent malaria. This, in part, is due to the fact that the Public Health system provides diagnosis and treatment of the disease free of charge. The specific diagnosis is promptly provided by the public health system of the Ministry of Health in Brazil, followed by treatment with antimalarials. In addition, human malaria is of compulsory notification to the Public Health system, that also controls the antimalarial drug distribution, under the State governments in Brazil (Ministério, 2020). Treatment is only provided after the parasite species has been parasitologically confirmed, and it varies according to the diagnosis of the species of parasite, which at present is mainly *P. vivax* followed by *P. falciparum*. The malaria endemic areas are restricted to the Amazon region in Brazil and its neighbouring countries in South America: Colombia, Peru and Venezuela and the Guianas (Figure 8).

In the Amazon region, the Quilombolas are endowed with extensive experience in the use of medicinal plants, as they have centuries of close contact with and dependence on local biodiversity as a means of livelihood and therapeutic resources. This fact makes the traditional communities attractive for groups conducting ethno-directed studies for medicinal plants used against malaria and other diseases (Oliveira et al., 2015). The popular uses of one species of

---

**TABLE 3** (Continued) Antimalarial activities and toxicities of medicinal plants evaluated in animal models from 2011 to 2020.

| Plant species          | Parasitemia Inhibition with each extract and dose used for the treatment of the malaria infected mice (dose in mg/kg body weight) | Increased survival of the malaria infected mice | Safe dose to non-infected mice (mg/kg body weight) |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Terminalia macroptera  | Leaves ethanolic extract 37% (100), roots ethanolic extract 46% (100)                                                         | Not improved                                     | 2,000                                           |
| Trichilia heudelotii   | Aqueous stem bark extract 40% (800)                                                                                          | NE                                               | NE                                              |
| Xylopia amazônica      | Aqueous leaf and branch extract 52% (250)                                                                                   | Not improved                                     | NE                                              |
| Zanthoxylum chalybeum  | Aqueous leaf extract 78% (100)                                                                                              | NE                                               | 2,000                                           |
| Zingiber officinale    | Methanolic root extract 33% (1,000)                                                                                         | Yes                                              | NE                                              |
| Ziziphus mauritiana    | Hydroethanolic stem bark extract 39% (200), 66% (400), 89% (600)                                                           | Yes                                              | NE                                              |

*NE, not evaluated. *Antimalarial activity evaluated in gametocytes.

---

**FIGURE 8** | Malaria by Annual Parasite Index (API) in the Americas (Pan American Health Organization, 2017), adapted by the authors. Source: https://www.paho.org/hq/index.php?option=com_topics&view=article&id=33&Itemid=40757&lang=en.
medicinal plant, *Ampelozzyphus amazonicus*, known as “Indian beer,” has been previously described, and found to be frequent among the indigenous people in the State of Amazon (Botelho et al., 1981; Brandão et al., 1985; Carvalho et al., 1991; Brandão et al., 1992; Kretti et al., 2001; Oliveira et al., 2011), and also common among the Quilombolas (Oliveira et al., 2011, 2015).

It has been demonstrated that the ethanolic extracts of *A. amazonicus* target the sporozoites, the infective form inoculated through the mosquito bite; *in vitro* and *in vivo* models were used in the study (Andrade-Neto et al., 2008). The animals treated with ethanolic extracts by oral route, prior to sporozoite inoculation intravenously, had a significantly prolonged malaria pre-patent period (which is the time elapsed between sporozoite inoculation and detection of parasitemia in the experimental animals). The treated mice had a lower parasitemia and a prolonged survival time, as compared to the untreated control mice infected with sporozoites. Additional *in vitro* tests clearly confirmed the *in vivo* results: sporozoites pre-incubated with the plant extracts, were less infective to host cells, as compared to control sporozoites in culture medium. In conclusion, the “Indian beer” ethanolic extract was shown to be a potent prophylactic against malaria (Bradão et al., 1985; Carvalho et al., 1991; Brandão et al., 1981; de Souza et al., 2017).

Unfortunately, very few groups studying the experimental activity of medicinal plants in the world have facilities to produce sporozoites for the *in vivo* and *in vitro* tests. Thus, compounds active against these forms, or against the intrahepatic parasites developed from sporozoites will not be discovered until such tests are more easily performed with medicinal plants aiming at new antimalarials. Our group has developed an experimental model to test extracts from plants against the sporogonic stages in mosquitoes as well as the tissue cycle of sporozoite development, using an avian malaria parasite *P. gallinaceum* and mosquitoes *Aedes*, which are susceptible to the species (Carvalho et al., 1992).

Another medicinal plant species frequently used to treat fevers and malaria in Brazil is *Bidens pilosa*, which is active against malaria and was listed as an antimalarial medicinal plant of interest to the Unified Health System in Brazil, largely based on experimental studies of our group (Andrade-Neto et al., 2004; Oliveira et al., 2004; Palhares et al., 2015). The ethanolic crude extracts from *B. pilosa* caused 60% reduction in parasitaemia at doses of 250 mg/kg in mice infected with *P. berghei*; importantly, the ethanolic extracts from *B. pilosa* were similarly active *in vitro* against *P. falciparum* chloroquine-resistant (clone W2) and chloroquine-sensitive parasites (clone D6) (Andrade-Neto et al., 2004).

Essential oils (EOs) have been considered as an important class of antimalarial natural products with low molecular weight components, rich in monoterpens and sesquiterpenes, found specially in plants native to Northeast Brazil (Mota et al., 2012). Thus, EOs obtained from *Vanillosmopsis arborea* (Asteraceae) were active sub-cutaneously, causing up to 47% inhibition of parasitemia in mice. EOs present in *Lippia sidoides* Cham. (Verbenaceae) and in *Croton zehntneri* (Euphorbiaceae) were active by oral route, causing 43–55% malaria growth inhibition, respectively, although no dose response activity was observed. The active EOs had monoterpene and phenylpropanoid compounds like estragole, α-bisabolol and thymol active *in vitro* against *P. falciparum* but not tested in mice with malaria (Mota et al., 2012). Another plant that contains an oleoresin rich in sesquiterpenes and diterpenes, but with high *in vivo* activity, is *Copaifera reticulata*, a tree distributed throughout the Amazon region, which has β-caryophyllene as its major compound, and caused a reduction of 93% in parasitemia when it was tested in mice (de Souza et al., 2017).

A high antimalarial activity has been described in the extracts of another 11 Brazilian medicinal plants, namely, *Chenopodium ambrosioides* (Cysne et al., 2016), *Xylopia amazonica* (Lima et al., 2015), *Aspidosperma nitidum* (Coutinho et al., 2013), *A. olivaceum* (Chierito et al., 2014), *A. pyrifolium* (Ceravolo et al., 2018), *A. ramiiflorum* (Aguiar et al., 2015), *Euterpe oleracea* (Ferreira et al., 2019), *Caesalpinia pluviosa* (Kayano et al., 2011), *Copaifera reticulata* (de Souza et al., 2017), *Piper peltatum* (Rocha e Silva et al., 2011) and *Andropogon leucostachyus* (Lima et al., 2015); all of them have been described as active against experimental malaria in mice and also *in vitro* against *P. falciparum*. The cited genus *Aspidosperma* spp. was the most studied among the Brazilian plants in the last 10 years, and has been considered for further studies in drug development; the species *A. pyrifolium* (at 100 mg/kg) and *A. olivaceum* (at 100 and 200 mg/kg) were the most potent *in vivo* against *P. berghei* murine malaria, with a parasitemia reduction of 75–93% for *A. pyrifolium* (Ceravolo et al., 2018), and 58 and 79% for *A. olivaceum* respectively (Chierrito et al., 2014) (Tables 1, 2).

### Natural Products Isolated From Medicinal Plants and Their Activities

Of all the antimalarial medicinal plants studied from 2011 to 2020, very few have their active principles isolated and characterized, such as *Coptis japonica*, *Heinsia crinita*, *Piper peltatum* and *Murraya koenigii*. Some of the active principles have been previously isolated from other plants while others are novel. Most of the studies carried out on the active principles are mainly *in vitro* studies. This is partly due to the fact that these compounds were isolated in small amounts that allowed only *in vitro* studies, not a main focus of this review. To overcome such bottle-neck, it is important to start the process of isolation of compounds using large amount of plant materials. The isolated compounds evaluated for *in vivo* antimalarial activities were: 1) Coptisine Chloride from *Coptis japonica*, (Teklemichael et al., 2020); 2) 4-Nerolidylcatechol isolated from *Piper peltatum* (Rocha e Silva et al., 2011); and 3) Myristic Acid and β-Caryophyllene from *Murraya koenigii* (Kamaraj et al., 2014) (Tables 2, 3).

In the studies with *Piper peltatum*, very high doses of 4-Nerolidylcatechol, the active principle (400 and 600 mg/kg body weight), have been tested, resulting in chemosuppression of 34.4 and 63.1%, respectively, in *P. berghei* NK65-infected mice (Rocha e Silva et al., 2011). Such high doses are not clinically
feasible for human use; thus, efforts should be directed towards the development of compounds with higher activities at low doses as antimalarial drugs. The 4-day suppressive test (Peters, 1965) was used for all the in vivo studies. However, one of the studies failed to determine the parasitaemia of day 4 post-inoculation, which is very important for identifying the fast acting compounds against malaria. It is only the slow acting compounds that are left till days 5, 6, and 7 post-inoculation (Fidock et al., 2004).

One of the compounds, Coptis Chloride, was administered intraperitoneally, which is not the conventional route of administration for in vivo studies in murine malaria. The pharmacokinetic parameters of the drugs administered via such route are different from those of conventionally used routes of administration and therefore, they are not applicable to humans (Teklemichael et al., 2020).

Some pure compounds such as Aspidoscarpine, Uleine, Apparicine, and N-Methyl-Tetrahydrodihydravicine were isolated from *A. olivaceum* (Chierrito et al., 2014), Isositrikine, 10-Methoxygeissoschizol and Ramiflorine were isolated from *A. ramiflorum* (Aguiar et al., 2015), and the bisindole alkaloid Leucoridine B was isolated from *A. pyrifolium* (Ceravolo et al., 2018); but none of these pure compounds was tested in the experimental mouse model. Braznitidiumine was isolated from *A. nitidum* (Coutinho et al., 2013), but it was not active against *P. berghei* in experimentally infected mice.

Only one compound was tested against the life cycle in the mosquito, namely, Daucovirgolide G extracted from the plant *Daucus virgatus*; it is impressive that it inhibits 92% of the early sporogonic stages of the parasite at 50 µg/ml (Sirignano et al., 2019; Table 4). This transmission blocking activity appears to be related to the presence of an intact endocyclic double bond system of the compound, that interacts with the biological target (Sirignano et al., 2019). This structural part is obviously lacking in Daucovirgolide J, which is the reason for its lack of activity (Sirignano et al., 2019).

Africa has a rich flora, ranging from the Savannah to the rainforest, with diversity of phytochemicals and other biomolecules which possess various pharmacological activities, some of which have been extensively reviewed elsewhere (Moyo et al., 2015; Van Wyk, 2015; Ahmed et al., 2018; Oguntibeju, 2018; Van Vuuren and Frank, 2020). Many plants have been reported to be used for the treatment of malaria in the African continent (Soh and Benoit-Vical, 2007; Pillay et al., 2008; Adebayo and Kretli, 2011; Maranz, 2012; Chinsembu, 2015; Memvanga et al., 2015; Omara et al., 2020). As the use of *Cinchona* species (from which quinine was isolated) for the treatment of malaria dates back to the 1700s (Guerra, 1977; Lee, 2002), the use of some plants, such as *Azadirachta indica* and *Alstonia broonii*, for the treatment of malaria, indigenously, in the African continent dates back to centuries, though this has not been properly documented. More recently, the efficacies of some of these medicinal plants have been scientifically authenticated and their active principles isolated, with the mechanisms of action of some of them delineated. However, none of the isolated compounds has been developed into drugs to be used clinically for the treatment of malaria, as reviewed below.

The mechanisms of action of most isolated compounds from the medicinal plants are unclear and/or were only studied in vitro against *P. falciparum*. This is the case of Coptisine, isolated from *Coptis japonica*, which exhibits its activity by inhibiting *P. falciparum* dihydroorotate dehydrogenase, an enzyme required for the synthesis of pyrimidine in the parasite (Lang et al., 2018). The authors reported that the kinetic parameters obtained revealed that coptisine was an uncompetitive inhibitor of the enzyme. Berberine, isolated from *Coptis japonica*, has been shown to inhibit telomerase activity in *P. falciparum* (Sriwilaijareon et al., 2002), but there are no documents of studies with their activities in the malaria infected mice.

The chemical structure and molecular formula of each isolated compound are shown in Table 5.

**Acute and Sub-Chronic Toxicity of Some Isolated Compounds**

Some of the compounds isolated from *Coptis japonica* (Teklemichael et al., 2020), *Piper peltatum* (Rocha e Silva et al., 2011) and *Murraya koenigii* (Kamaraj et al., 2014) plants have been evaluated for their acute toxicities (Table 4). None of them could be declared safe, having oral LD$_{50}$ values that are less than 5,000 mg/kg body weight (Lorke, 1983). Among the compounds evaluated for acute toxicity, Palmatine was the least toxic with the highest oral LD$_{50}$ value. However, many of the isolated compounds have not been evaluated for their acute toxicity. This may also be due to fact that these compounds were isolated in small amounts which were not sufficient enough to allow their being tested for acute toxicity. Other compounds were tested by intraperitoneal route.

### TABLE 4 | Acute toxicities of antimalarial compounds isolated from medicinal plants.

| Plant species | Names of compounds | Animal | Route   | LD$_{50}$ (mg/kg body weight) | References               |
|---------------|--------------------|--------|---------|-------------------------------|--------------------------|
| *Coptis japonica* | Palmatine | Mouse | Oral   | 1,533.68                      | Yi et al. (2013)          |
|               | Berberine         | Mouse  | Intraperitoneal | 57.6103                   | Kheir et al. (2010)      |
|               | Coptisine         | Mouse  | Oral   | 713.57                         | Yi et al. (2013)            |
| *Murraya koenigii* | Myristic Acid | Mouse | Intravenous | 9.0386                      | Kheir et al. (2010)      |
| *Piper peltatum*   | 4-Nerolidylcatechol | Mouse | Oral   | 673.22                         | Mendanha da Cunha et al. (2013) |
TABLE 5 | Some antimalarial compounds isolated from medicinal plants.

| Isolated compound | Molecular formula | Chemical structure |
|-------------------|-------------------|--------------------|
| Coptisine chloride | C₁₉H₁₄ClNO₄ | ![Coptisine chloride](image1) |
| 4-Nerolidylcatechol| C₂₁H₃₀O₂ | ![4-Nerolidylcatechol](image2) |
| Myristic acid     | C₁₄H₂₉O₂ | ![Myristic acid](image3) |
| β-Caryophyllene   | C₁₅H₂₄ | ![β-Caryophyllene](image4) |
| Aspidoscarpine    | C₁₁H₁₈N | ![Aspidoscarpine](image5) |
| Uleine            | C₁₉H₂₀N₂ | ![Uleine](image6) |
| Apparicine        | C₁₈H₂₀N₂ | ![Apparicine](image7) |
| N-Methyl-tetrahydrolicine | C₁₈H₂₀N₂ | ![N-Methyl-tetrahydrolicine](image8) |
| Isositrikine      | C₂₁H₂₆N₂O₃ | ![Isositrikine](image9) |

(Continued on following page)
(Berberine) or by intravenous route (Myristic Acid) which are not routes used traditionally for the treatment of malaria in humans.

The subchronic systemic toxicity, defined as adverse effects occurring after the repeated or continuous administration of a test sample for up to 90 days, does not

| Isolated compound       | Molecular formula | Chemical structure |
|-------------------------|-------------------|--------------------|
| 10-Methoxygeissoschizol | C_{20}H_{26}N_{2}O_{2} | ![Chemical structure](image) |
| Ramiflorine A and B    | C_{30}H_{34}N_{4}O  | ![Chemical structure](image) |
| Leucoridine B           | C_{38}H_{42}N_{4}   | ![Chemical structure](image) |
| Braznitidumine          | C_{24}H_{32}N_{4}O_{6} | ![Chemical structure](image) |
| Daucovirgolide G       | C_{25}H_{30}O_{7}   | ![Chemical structure](image) |
| Berberine               | C_{20}H_{18}NO_{4}  | ![Chemical structure](image) |
seem to be related to the extracts that have been used against malaria; furthermore, only Coptisine Chloride was tested in vivo (Teklemichael et al., 2020) (Table 3). Other studies have shown that administration of Palmatine, Coptisine and Berberine, at the dose of 156 mg/kg body weight, did not exert nephrotoxic or hepatotoxic effects, though Palmatine significantly increased ($p < 0.05$) plasma total bilirubin concentration compared to control (Yi et al., 2013). However, the authors did not proceed further to identify whether hemolysis, impaired conjugation of bilirubin in the liver or excretion of conjugated bilirubin into the bile duct was responsible for such increase. Many of the compounds have not been evaluated for sub-chronic toxicity or for chronic toxicity. This has limited the determination of the no adverse effect levels (NOAEL) and low adverse effect levels (LOAEL) of the compounds.

**Genotoxicity**

Berberine, a compound isolated from *Coptis japonica* (Table 4), has been reported not to be genotoxic for prokaryotic cells (Pasqual et al., 1993); however, it has been reported to be genotoxic to dividing eukaryotic cells by intercalating with the DNA (Jennings and Ridler, 1983). Palmatine has been reported to exert genotoxicity causing DNA double strand breaks, though to a lesser extent than Berberine (Chen et al., 2013). Both compounds have been reported to inhibit topoisomerase I and II activities, thereby inhibiting DNA relaxation and decatenation during replication (Chen et al., 2013). Inhibition of DNA decatenation results in the stabilization of topo II-DNA complexes (Li et al., 2010), thereby enhancing the induction of DNA double strand breaks. Palmatine has been reported to interact with DNA by binding to the groove of DNA (Mi et al., 2015). Knipholone and knipholone anthrone have been reported not to cause DNA damage on their own but knipholone anthrone caused DNA damage in the presence of copper ions through the generation of hydrogen peroxide (Habtemariam and Dagne, 2009). 4-Nerolidylcathexol has been shown to exhibit low genotoxicity compared to negative control. However, 4-Nerolidylcathexol has been reported to protect against cyclophosphamide-induced DNA damage by scavenging the free radicals generated by cyclophosphamide (Valadares et al., 2007).

**Mutagenicity**

It has been reported that berberine, in the absence of microsomal fraction S9, was weakly mutagenic in *Salmonella typhimurium* TA98, a frameshift detecting strain (Nozaka et al., 1990). It did not cause an increase in the frequency of point mutation (Pasqual et al., 1993) under conditions in which the frameshift mutation was increased by a factor of 4 in *Saccharomyces cerevisiae* using this model (Pasqual et al., 1993). None of the studies evaluated the mutagenic activities of the compounds using the murine malaria parasite model which analyses the micronucleated cells (Tometsko et al., 1993).

**Carcinogenicity, Reproductive Toxicity and Allergenicity**

Several purified compounds exert carcinogenic effects after accumulation, over time, in cellular systems. The searches made on PubMed and PubChem revealed that the above isolated compounds have not been evaluated for carcinogenic and allergenic effects. Their effects on pregnancy, such as absorption of fetus, and teratogenic effects have not been evaluated. This indicates that all the isolated compounds have not fully gone through the process of drug development. Consequently, not a single one of them has been developed into an antimalarial drug, neither been subjected to clinical trials.

**CONCLUSION AND FUTURE PERSPECTIVES**

Of the seventy one manuscripts published in the past 10 years that evaluated the antimalarial activities of extracts and isolated compounds from plant species in rodent malaria model, most of them aimed the erythrocytic stages of the parasite, which are responsible for the malaria symptoms. Only one compound was tested against the early sporogonic stages of the parasite. In addition, a few active principles were described. All steps of extractions, from the pre-extraction to final extraction are equally important in the study of medicinal plants, and play a critical role in the outcomes, including the product yield and phytochemical characterization; and these steps seem to interfere in the final product activity (Azwanida, 2015). Most of the experimental studies of plant materials used organic solvents, in spite of the recommendation in the specific literature that only water and ethanol should be used in traditional preparations for medical use (Willcox et al., 2011). Taken together, these facts explain the reduced contribution of Africa, in the past 10 years, to the achievement of the Medicine for Malaria Venture objective, which is the development of a new antimalarial drug every 5 years. The reason for this is not far-fetched but in part, it is due to the gross lack of standard facilities for antimalarial drug development in various countries of the African continent, which is responsible for most of the antimalarial tests herein described, especially in countries like Ethiopia and Nigeria, where most of the results have been published in the last 10 years. It is believed that technological advancement in the African continent and the world at large, will certainly go a long way in tackling this fundamental problem, thereby liberating the continent from the scourge of this disease.

**AUTHOR CONTRIBUTIONS**

IC designed the figures and prepared the tables; AA performed the bibliographic survey of the articles; JA wrote about plant isolated compounds, their toxicity, genotoxicity, mutagenicity and carcinogenicity; AK supervised the work and critically reviewed the manuscript. All the authors contributed to writing and analysing the paper.
FUNDING

This work was supported by a grant from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 409751/2018-9, and FASESP 2019/19708-0, Brazil. AK is a recipient of a Senior Fellowship from CNPq, Brazil.

REFERENCES

Abay, S. M., Lucantoni, L., Dahiya, N., Dori, G., Dembo, E. G., and Esposito, F. (2015). *Plasmodium Transmission Blocking Activities of Vernonia Amygdalina Extracts and Isolated Compounds*. *Malar. J.* 14, 288. doi:10.1186/s12936-015-0812-2

Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Balrine, F. N., et al. (2011). Quinine, an Old Anti-malarial Drug in a Modern World: Role in the Treatment of Malaria. *Malar. J.* 10, 144. doi:10.1186/1475-2875-10-144

Adebayo, J. O., and Krettli, A. U. (2011). Potential Antimalarials from Nigerian Plants: A Review. *J. Ethnopharmacol.* 133, 289–302. doi:10.1016/j.jep.2010.11.024

AdenAbdi, Y., Gustafsson, L. L., Ericsson, O., and Hellgren, U. (1995). *Antimalarial Activity of Extracts from Three Medicinal Plants Used in Malaria Treatment in Nigeria*. *Em. J. Ethnopharmacol.* 51, 373–377.

Aguiar, A. C., Cunha, A. C., Ceravolo, I. P., Gonçalves, R. A., Oliveira, A. J., and Alli, L. A., Adesokan, A. A., and Salawu, A. O. (2016). Antimalarial Activity of Roots of Stem Bark of *Periploca Linearifolia*. *J. Intercult. Ethnopharmacol.* 8, 1505–1511. doi:10.1016/j.jipe.2008.05.007

Andrade-Neto, V. F., Brandão, M. G., Stehmann, J. R., Oliveira, L. A., and Krettli, A. U. (2003). Antimalarial Activity of *Aspidosperma Rami* Fl. *J. Ethnopharmacol.* 87, 253–256. doi:10.1016/s0378-8749(03)00141-7

Ansiari, M. T., Saify, Z. S., Sultana, N., Ahmad, I., Saeed-ul-Hassan, S., Tariq, I., et al. (2013). Malaria and Artemisinin Derivatives: an Updated Review. *Mini Rev. Med. Chem.* 13, 1879–1902. doi:10.2174/1389557511313660097

Arrey, F., Witurowski, B., Amarantunga, C., Beghain, J., Langlois, A. C., Kimh, N., et al. (2014). A Molecular Marker of Artemisinin-Resistant *Plasmodium Falciparum* Malaria. *Nature* 505, 50–55. doi:10.1038/nature12876

Asnake, S., Teklehaimanot, T., Hymete, A., Erko, B., and Giday, M. (2015). Evaluation of the Antiplasmodial Properties of Selected Plants in Southern Ethiopia. *BMC Complement. Altern. Med.* 15, 448. doi:10.1186/s12906-015-0976-x

Asrade, S., Mengesha, Y., Moges, G., and Gelaye, D. A. (2017). In Vivo antimalarial Activity Evaluation of the Leaves of *Balantiana Rotundifolia* (Van Tiegh.) Blatter (Balantianeae) against *Plasmodium Berghei*. *J. Exp. Drugs* 9, 59–66. doi:10.2147/JEP.S130491

Asua, V., Conrad, M. D., Aydemir, O., Duvalsaaint, M., Legac, J., Duarte, E., et al. (2021). Changing Prevalence of Potential Mediators of Aminopquinoline, Antifolate, and Artemisinin Resistance across Uganda. *J. Infect. Dis.* 223, 985–994. doi:10.1093/infdis/jiaa687

Asua, V., Vinden, J., Conrad, M. D., Legac, J., Kigozi, S. P., Kamya, M. R., et al. (2019). Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda. *Antimicrob. Agents Chemoter.* 63, e01818–18. doi:10.1128/AAC.01818-18

Atteme, S. D. D., Beourou, S., Tuo, K., Gnondjui, A. A., Konate, A., Toure, A. O., et al. (2018). Antiplasmodial Activity of Two Medicinal Plants against Clinical Isolates of *Plasmodium Falciparum* and *Plasmodium Berghei* Infected Mice. *J. Parasit. Dis.* 42, 68–76. doi:10.1016/j.jpsd.2018.01.014

Awazanian, N. N. (2015). A Review on the Extraction Methods Use in Medicinal Plants, Principle, Strength and Limitation. *Med. Aromat. Plants* 4, 3. doi:10.4172/2167-0412.1000196

Balint, G. A. (2001). Artemisinin and its Derivatives: an Important New Class of Antimalarial Agents. *Pharmacol. Ther.* 90, 261–265. doi:10.1016/s0163-7258(01)00140-1

Bankole, A. E., Endale Gurmu, A., and Wubneh, Z. B. (2018). Antimalarial Activity of Stem Bark of *Periploca Linearis* during Early and Established *Plasmodium* Infection in Mice. *Evid-based Compl. Alt. Med.*. doi:10.1155/2018/4169397

Berth, W., González, A., Rios, A., Blair, S., Cogollo, Á., and Pabón, A. (2018). Phytochemical Screening and In Vivo Antimalarial Activity of Extracts from Three Medicinal Plants Used in Malaria Treatment in Nigeria. *Parasitol. Res.* 115, 299–305. doi:10.1007/s00436-015-4747-x

Bintie, L., Assefa, S., Teklehaimanot, T., and Engidawork, E. (2014). In Vivo antimalarial Activity of the Crude Leaf Extract and Solvent Fractions of *Croton Macroystachys* Hochst. (Euphorbiaceae) against *Plasmodium Berghei* in Mice. *BMC Complement. Altern. Med.* 14, 79–89. doi:10.1186/s1472-6882-14-79

Belay, W. Y., Endale Gurmu, A., and Wubneh, Z. B. (2008). Antimalarial Activity of Stem Bark of *Periploca Linearis* during Early and Established *Plasmodium* Infection in Mice. *Evid-based Compl. Alt. Med.*. doi:10.1155/2018/4169397

Best Plummer, W., and Pinto Pereira, L. (2008). Diminished *Plasmodium Falciparum* Sensitivity to Quinine Exposure In Vivo and in a Sequential Multi-Drug Regimen: A Preliminary Investigation in Guyana, South America. *Int. J. Infect. Dis.* 12, 27–31. doi:10.1016/j.ijid.2008.03.024

Biruk, H., Sentayehu, B., Abebechew, Y., Tamiru, W., Ejigu, A., and Assefa, S. (2020). In Vivo antimalarial Activity of 80% Methanol and Aqueous Bark Extracts of *Terminalia Brownii* Fresen. (Combretaceae) against *Plasmodium Berghei* in Mice. *BMC Complement. Altern. Med.* 20, 7. doi:10.1186/s12936-018-2301-x

Biruk, H., Mammo, W., Hymet, A., and Yeshak, M. Y. (2017). Antimalarial Activity of 50% Ethanol Extracts from *Echinops Hoehnelii* Schweinf. *Molecules* 22, 1965. doi:10.3390/molecules2211965

ACKNOWLEDGMENTS

All authors are deeply thankful to Dr. Virgilio do Rosario, for his excellent and generous work on the English review. We are also thankful to Professor Ricardo T Gazzinelli for financial support to the fee to publish the review.
Habtemariam, S., and Dagne, E. (2009). Proxidant Action of Kniphofine Anthrone: Copper Dependent Reactive Oxygen Species Generation and DNA Damage. Food Chem. Toxicol. 47, 1490–1494. doi:10.1016/j.fct.2009.03.032

Haddad, M., Mahboobdr, H., Zamani, Z., and Ramazani, A. (2017). Antimalarial Evaluation of Selected Medicinal Plant Extracts Used in Iranian Traditional Medicine. Iran. J. Basic Med. Sci. 20, 415–422. doi:10.22038/IEJ.BMS.2017.8583

Haidara, M., Haddad, M., Denou, A., Marti, G., Bourgeade-Delmas, S., Sanogo, R., et al. (2018). In Vivo validation of Anti-malarial Activity of Crude Extracts of Terminalia macroptera, a Malian Medicinal Plant. Malar. J. 17, 68. doi:10.1186/s12936-018-2223-7

Hallesløe, G. G., Rajeshwary, Y., Haulu, G. S., Sibhat, G. G., and Bitew, H. (2020). In Vivo antimalarial Evaluation of Crude Extract, Solvent Fractions, and TLC-Isolated Compounds from Olea europaea Linn. Subsp. Caspidea (Oleaceae). Evid-based Compl. Alt. Med. 2020, 6713485. doi:10.1155/2020/6713485

Hien, T. T., and White, N. J. (1993). Qinghaosu. Malar. J. 10, 112. doi:10.1186/1475-2875-10-112

Kefe, A., Giday, M., Mamo, H., and Erko, B. (2016). Antimalarial Properties of Crude Extracts of Seeds of Brueca antisypdererca and Leaves of Ocimum Lamisilioum. BMC Complement. Altern. Med. 16, 118. doi:10.1186/s12906-016-1098-9

Kheir, M. M., Wang, Y., Hua, L., Hu, J., Li, L., Lei, F., et al. (2010). Acute Toxicity of Berberine and its Correlation with the Blood Concentration in Mice. Food Chem. Toxicol. 48, 1105–1110. doi:10.1016/j.fct.2010.01.033

Kifle, Z. D., Adinew, G. M., Mengistie, M. G., Gurmu, A. E., Enyew, E. F., Goshu, B. T., et al. (2020). Evaluation of Antimalarial Activity of Methanolic Root Extract of Myrica salicifolia A Rich (Myricaceae) Against Plasmodium berghei-Infected Mice. J. Evid. Based Integr. Med. 25, 2515690X20920539. doi:10.1155/2020/2515690X20920539

Kifle, Z. D., and Atanfie, S. A. (2020). Anti-oxidant Potential and Antimalarial Effects of Acantus Polystachyus Delile (Acanthaceae) against Plasmodium Berghei: Evidence for In Vivo Antimalarial Activity. J. Exp. Pharmaco. 12, 575–587. doi:10.2147/JEP.S28407

Kraithe, M. N., Nguta, J. M., Mbaria, J. M., and Kiama, S. G. (2016). Evaluation of the Use of Ocimum Suave Willd. (Lamiaceae), Plectranthus Barbadus Andrews (Lamiaceae) and Zanthoxylum Chalybeum Engl. (Rutaceae) as Antimalarial Remedies in Kenyan Folk Medicine. J. Ethnopharmacol. 178, 266–271. doi:10.1016/j.jep.2015.12.013

Klaman, D. L. (1985). Qinghaosu (Artemisinin): an Antimalarial Drug from China. Science 228, 1049–1055. doi:10.1126/science.3887571

Kretli, A. U., Andrade-Neto, V. F., Brandão, M. G., and Ferrari, W. M. (2001). The Search for New Antimalarial Drugs from Plants Used to Treat Fever and Malaria or Plants Randomly Selected: a Review. Mem. Inst. Oswaldo Cruz 96, 1033–1042. doi:10.1590/S0076-02672001000800002

Krishna, S., Bustainante, L., Haynes, R. K., and Staines, H. M. (2008). Artemisinins: Their Growing Importance in Medicine. Trends Pharmacol. Sci. 29, 520–527. doi:10.1016/j.tips.2008.07.004

Kutchan, T. M. (2001). Ecological Arsenal and Developmental Dispatcher. The Paradigm of Secondary Metabolism. Plant Physiol. 125, 58–60. doi:10.1104/pp.125.1.58

Kweyamba, P. A., Zofou, D., Efang, N., Assob, J. C. N., Kitas, J., and Nyindo, M. (2019). In Vitro and In Vivo Studies on Anti-malarial Activity of Commiphora africana and Dickrostachys cineraei Used by the Maasai in Arusha Region, Tanzania. Malar. J. 18, 119. doi:10.1186/s12936-019-2752-8

Lahlou, M. (2007). Screening of Natural Products for Drug Discovery. Expert Opin. Drug Disc. 2, 697–705. doi:10.1517/17464412.5.2.697

Lampah, D. A., Yeo, T. W., Hardianto, S. O., Tjipta, E., Kenangalem, E., Sugarto, P., et al. (2011). Coma Associated with Microscopy-Diagnosed Plasmodium Vivax: A Prospective Study in Papua, Indonesia. Plos Negl. Trop. Dis. 5, 1032. doi:10.1371/journal.pntd.0001032

Lang, L., Hu, Q., Wang, J., Liu, Z., Huang, J., Lu, W., et al. (2018). Coptisine, a Natural Alkaloid from Coptidis Rhizoma, Inhibits Plasmodium falciparum Dihydroorotate Dehydrogenase. Chem. Biol. Drug Des. 92, 1324–1332. doi:10.1111/cbld.13197

Lee, M. R. (2002). Plants against Malaria. Part 1: Cinchona or the Peruvian Bark. J. R. Coll. Physicians Edinb. 32, 189–196. doi:10.1097/0000287.143.

Legrand, E., Volney, B., Meynard, J. B., Mercereau-Puijalon, O., and Esterre, P. (2008). Artemisia annua and Reaction of Arteannuin. Antimicrob. Agents Chemother. 42, 298–299. doi:10.1128/AAC.00263-07

Li, Y., Luan, Y., Qi, X., Li, M., Gong, L., Xue, X., et al. (2010). Emodin Triggers DNA Double-Strand Breaks by Stabilizing Topoisomerase II-DNA Cleavage Complexes and by Inhibiting ATP Hydrolysis of Topoisomerase II. Toxicol. Sci. 118, 435–443. doi:10.1093/toxsci/kfp282

Lim, R. B., Rocha e Silva, L. F., Melo, M. R., Costa, J. S., Picâncio, N. S., Lima, E. S., et al. (2015). In Vitro and In Vivo Anti-malarial Activity of Plants from the Brazilian Amazon. Malar. J. 14, 308. doi:10.1186/s12936-015-0099-2

Liu, J. M., Ni, M. Y., Fan, J. F., Tu, Y. Y., Wu, Z. H., Wu, Y. L., et al. (1979). Structure Reaction of Arteannuin. Acta Chim. Sin. 37, 129–143.

Lorke, D. (1983). A New Approach to Practical Acute Toxicity Testing. Arch. Toxicol. 54, 275–287. doi:10.1007/BF02134480

Maranz, S. (2012). An Alternative Paradigm for the Role of Antimalarial Plants in Africa. Sci. World J. 978913. doi:10.1155/2012/978913

Mathieu, L. C., Cox, H., Early, A. M., Mok, S., Lazeek, Y., Paquet, J. C., et al. (2020). Local Emergence in Amazonia of Plasmodium falciparum K13 C880Y Mutants
Associated with In Vitro Artemisinin Resistance. Elife 9, e51015. doi:10.7554/ eLife.51015

Mandé, R. J., Woodrow, C. J., and White, L. J. (2010). Artemisinin Antimalarials: Preserving the "magic bullet. Drug Dev. Res. 71, 12–19. doi:10.1002/ddr.20344

Mayxay, M., Barends, M., Brockman, A., Jaidee, A., Nair, S., Sudimack, D., et al. (2007). In Vitro antimalarial Drug Susceptibility and Pfort Mutation Among Fresh Plasmodium Falciparum Isolates from the Lao PDR (Laos). Am. J. Trop. Med. Hyg. 76, 245–250. doi:10.4269/ajtmh.2007.76.245

Memvanga, P. B., Tona, G. L., Mesia, G. K., Lusakabanza, M. M., and Cimanga, R. K. (2015). Antimalarial Activity of Medicinal Plants from the Democratic Republic of Congo: A Review. J. Ethnopharmacol. 169, 76–98. doi:10.1016/j.jep.2015.03.075

Mendhana da Cunha, C. R., Mendanha Neto, S. A., Carlos da Silva, C., Cortez, A. P., Gomes, M. N., Martins, F. I., et al. (2013). 4-Nerolidylacetechol and its Synthetic Analogues: Antioxidant Activity and Toxicity Evaluation. Eur. J. Chem. 62, 371–386. doi:10.1515/ejchem.2012.028

Menkin-Smith, L., and Winders, W. T. (2020). Plasmodium Vivax Malaria. Treasure Island, FL: StatPearls.

Mesfin, A., Giday, M., Animat, U., and Teklehaimanot, T. (2012). Ethnobotanical Study of Antimalarial Plants in Shinline District, Somali Region, Ethiopia, and In Vivo Evaluation of Selected Ones against Plasmodium Berghei. J. Ethnopharmacol. 139, 221–227. doi:10.1016/j.jep.2011.11.006

Mesnick, S. R. (1998). Artemisinin Antimalarials: Mechanism of Action and Resistance. Med. Trop. (Mars) 58, 13–17.

Mi, R., Tu, B., Bai, X. T., Chen, J., Ouyang, Y., and Hu, Y. J. (2015). Binding Properties of Palmitine to DNA: Spectroscopic and Molecular Modeling Investigations. Luminescence 30, 1344–1351. doi:10.1007/bio.2904

Ministério, d. S. (2020). Malária. Boletim Epidemiológico Secretaria de Vigilância em Saúde. Available at: https://www.gov.br/saude/pt-br/assuntos/media/pdf/e1009133. doi:10.1371/journal.ppat.1009133

Missal, F., Kelch13 C580Y Mutations on the Island of New Guinea. Elife 7, 78, 658. doi:10.7554/eLife.21783.

Nadja, N. A. C., Cédric, Y., Christian, N. O., Raoul, S. N. S., Jeanette, Y., Abdel Aziz, M., et al. (2020). In Vivo antimalarial Activity of Entandrophragma Cylindrophylla (Sprague) sprague Ethyl Acetate Extract in Plasmodium Berghei-infected Mice. J. Parasitol. Res. 2020, 884606. doi:10.1155/2020/884606

Neiva, A. (1987). Memória das memórias [Memoir of the Memories. Development of malaria hematozoa resistant to quinine. By Arthur Neiva, 1910]. Mem. Inst. Oswaldo Cruz 82, 303–309.

Nguta, J. M., and Mbaria, J. M. (2013). Brine Shrimp Toxicity and Antimalarial Activity of Some Plants Traditionally Used in Treatment of Malaria in Msambweni District of Kenya. J. Ethnopharmacol. 148, 988–992. doi:10.1016/j.jep.2013.05.053

Nieves, K., Prudhomme, J., Le Roch, K. G., Franzblau, S. G., and Rodriguez, A. D. (2016). Natural Product-Based Synthesis of Novel Antifungal Isoquinoline and Isooxalenylisoquinoline Functionalized Amphiethane Diterpenes. Bioorg. Med. Chem. Lett. 26, 854–857. doi:10.1016/j.bmcl.2015.12.080

Noedl, H., Se, Y., Schaecher, K., Smith, B. L., Soechet, D., and Fukuda, M. M. (2008). Evidence of Artemisinin-Resistant Malaria in Western Cambodia. N. Engl. J. Med. 359, 2619–2620. doi:10.1056/NEJMoa0805011

Nondo, S. R., Erasto, M. P., Moshi, J. M., Zacharia, A., Masimba, P. J., and Kidukuli, A. W. (2016). In Vivo antimalarial Activity of Extracts of Tanzanian Medicinal Plants Used for the Treatment of Malaria. J. Adv. Pharm. Technol. Res. 7, 59–63. doi:10.4103/2231-4040.179741

Nzimana, T., Watatane, F., Tadaki, S., Ishino, M., Morimoto, I., Kunitomo, J., et al. (1990). Mutagenicity of Isoquinoline Alkaloids, Especially of the Aporphine Type. Mutat. Res. 240, 267–279. doi:10.1016/0165-1218(90)90077-F

Nuyere, D., Assefa, S., Nedi, T., and Engidawork, E. (2018). Vivo Antimalarial Activity of the 80% Methanolic Root Bark Extract and Solvent Fractions of Gardenia Ternifolia Scuhman. & Thonn. (Rubiaceae) against Plasmodium Berghei. Evid-based Compl. Alt. Med., 9217835. doi:10.1155/2018/9217835

Oguntimebi, O. O. (2018). Medicinal Plants with Anti-inflammatory Activities from Selected Countries and Regions of Africa. J. Inflamm. Res. 11, 307–317. doi:10.2147/JIR.S167789

Olivera, D. R., Costa, A. L., Leitão, G. G., Castro, N. G., Santos, J. P., and Leitão, S. G. (2011). Ethnopharmacology Study of Saracuramia (Ameloplozyrrhus Amazonicus Ducke) in the “Quilombola” Communities of Oriximiná, Pará State, Brazil. Acta Amazon 41, 383–392. doi:10.1590/0044-99672010100300008

Olivera, D. R., Kretli, A. U., Aguiar, A. C., Leitão, G. G., Vieira, M. M., Martins, K. S., et al. (2015). Ethnopharmacological Evaluation of Medicinal Plants Used against Malaria by Quilombola Communities from Oriximiná, Brazil. J. Ethnopharmacol. 173, 424–434. doi:10.1016/j.jep.2015.07.035

Olivera, T., Andrade-Neto, V., Kretli, A. U., and Brandão, M. G. M. (2004). New Evidences of Antimalarial Activity of Bidens Pilosa Roots Extract Correlated with Polycateylene and flavonoids. J. Ethnopharmacol. 93, 39–42. doi:10.1016/j.jep.2004.03.026

Omar, T., Kiprop, A. K., Ramkat, R. C., Cherutoi, J., Kagoya, S., Moraa Nyangena, D., et al. (2020). Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Studies, Phytochemistry, and Anticancer Studies. Evid-based Compl. Alt. Med. 3529081. doi:10.1155/2020/3529081

Oro, L., and Wrettlin, A. (1961). Pharmacological Effects of Fatty Acids, Triolein and Cottonseed Oil. Acta Pharmacol. Toxicol. 18, 141–152. doi:1111/j.1600-0779.1961.tb00323.x

Ouji, M., Augereau, J. M., Paloque, L., and Benoit-Vical, F. (2018). Plasmodium Falciparum Resistance to Artemisinin-Based Combination Therapies: A Sword of Damocles in the Path toward Malaria Elimination. Parasite 25, 24. doi:10.1051/parasite/2018021

Palhares, R. M., Drummond, M. G., Dos Santos Alves Figueiredo Brasil, B., Cosenza, G. P., Brandão, M. G. L., and Oliveira, G. (2015). Medicinal Plants Recommended by the World Health Organization: DNA Barcode Identification Associated with Chemical Analyses Guarantees Their Quality. PLOS One 10, e0127866. doi:10.1371/journal.pone.0127866

Pan American Health Organization (2017). Report on the Situation of Malaria in the Americas - 2017. Available at: https://www.paho.org/hq/index.php?option=com_topics&view=article&id=40757&lang=en (Accessed June 29, 2021).

Pasqual, M. S., Lauer, C. P., Moyna, P., and Henriques, J. A. (1993). Genotoxicty of the Isoquinoline Alkaloid Berberine in Prokaryotic and
Four Species of Genus Ammanaria. Med. Chem. Res. 23, 870–876. doi:10.1007/s00044-013-0682-5
Uwimana, A., Legrand, E., Stokes, B. H., Ndikumana, J. M., Warsame, M., Umulisa, N., et al. (2020). Emergence and Clonal Expansion of In Vitro Artemisinin-Resistant Plasmodium Falciparum Kelch13 R561H Mutant Parasites in Rwanda. Nat. Med. 26, 1602–1608. doi:10.1038/s41591-020-1005-2
Valadares, M. C., Rezende, K. R., Pereira, E. R., Sousa, M. C., Gonçalves, B., de Assis, J. C., et al. (2007). Protective Effects of 4-nerolidylcatechol against Genotoxicity Induced by Cyclophosphamide. Food Chem. Toxicol. 45, 1975–1978. doi:10.1016/j.fct.2007.04.016
Van Agtmael, M. A., Eggelte, T. A., and Van Boxtel, C. J. (1999). Artemisinin Drugs in the Treatment of Malaria: from Medicinal Herb to Registered Medication. Trends Pharmacol. Sci. 20, 199–205. doi:10.1016/S0165-6147(99)01302-4
Van Vuuren, S., and Frank, L. (2020). Review: Southern African Medicinal Plants. Phytomedicine. 108, 4899–4914. doi:10.1016/j.ymjep.2019.112434
Van Wyk, B. E. (2015). A Review of Commercially Important African Medicinal Plants. J. Ethnopharmacol. 176, 118134. doi:10.1016/j.jep.2015.10.031
Wasunna, B., Zurovac, D., Goodman, C. A., and Snow, R. W. (2008). Why Don’t Health Workers Prescribe ACT? A Qualitative Study of Factors Affecting the Prescription of Artemether-Lumefantrine. Malar. J. 7, 29. doi:10.1186/1475-2875-7-29
Weissbuch, I., and Leiserowitz, L. (2008). Interplay between Malaria, Crystalline Hemozoin Formation, and Antimalarial Drug Action and Design. Chem. Rev. 108, 4899–4914. doi:10.1021/cr078274t
WHO (2018b). Artemisinin Resistance and Artemisinin-Based Combination Therapy Efficacy: Status Report. Switzerland: World Health Organization. Available at: https://apps.who.int/iris/handle/10665/274362 (Accessed June 21, 2021).
WHO (2015). Guidelines for the Treatment of Malaria. 3rd Edn. Switzerland: World Health Organization. Available at: https://www.afro.who.int/publications/guidelines-treatment-malaria-third-edition (Accessed June 21, 2021).
WHO (1998). Medicinal Plants in the Republic of Korea: Information on 150 Commonly Used Medicinal Plants. Philippines: World Health Organization Regional Publications, Regional Office for the Western Pacific, Manila. Available at: https://apps.who.int/iris/handle/10665/207585 (Accessed June 21, 2021).
WHO (2017). Status Report on Artemisinin and ACT Resistance Efficacy. Switzerland: World Health Organization. Available from: https://www.who.int/publications/i/item/WHO-CDS-GMP-2019.17 (Accessed June 21, 2021).
WHO (2020b). The World Malaria Report, the Malaria Atlas Project. Switzerland: World Health Organization. Available at: https://malariaatlas.org/trends/region (Accessed June 21, 2021).
WHO (2018a). World Malaria Report 2018. Ethiopia. Switzerland: World Health Organization. Available from: https://www.who.int/malaria/publications/country-profiles/profile_eth_en.pdf?ua=1 (Accessed June 21, 2021).
WHO (2019). World Malaria Report 2019. Switzerland: World Health Organization. Available from: https://www.who.int/publications/i/item/9789241565721 (Accessed June 21, 2021).
WHO (2020a). World Malaria Report 2020. Switzerland: World Health Organization. Available from: https://www.who.int/publications/i/item/9789240015791 (Accessed June 21, 2021).